The Drug Enforcement Administration (DEA) has proposed a substantial increase in the production quotas for psilocybin, psilocyn, and ibogaine for research purposes.
Dried psilocybin.
The agency’s revised quotas for Schedule I and II controlled substances are aimed at supporting clinical trials and research efforts. In its revised 2024 quotas, the DEA is proposing to increase the production of psilocybin from 20,000 grams to 30,000 grams and psilocyn from 24,000 grams to 36,000 grams, in addition to increasing the production of ibogaine from 150 grams to 210 grams. These elevated levels are expected to continue into 2025.
The proposal to change the 2024 quotas, and to extend them into 2025, was published in the Federal Register, a legal requirement.
The DEA is proposing that the research quotas for marijuana, THC, and MDMA stay the same as 2023 and 2024, going into 2025. The annual production quota for marijuana is 6,675,000 grams. The quota for MDMA is 12,000 grams.
In the Federal Register posting, the DEA says “These proposed increases are to support research and clinical trials by DEA-registered Schedule I researchers. The proposed increases demonstrate DEA’s support for research with Schedule I controlled substances and reflect research and development needs as part of the process for seeking FDA approval of new drug products.”
